There are currently 979 clinical trials in San Antonio, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Health Science Center at San Antonio, GSK Investigational Site, Pfizer Investigational Site and Methodist Children's Hospital of South Texas. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
NCT06857955
Recruiting
The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hypertension
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/07/2025
Locations: Sun Research Institute, San Antonio, Texas
Conditions: Hypertension
Register for Updates
A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389
NCT06812780
Recruiting
The purpose of this study is to examine the safety and tolerability of AZD2389 in participants with hepatic impairment and participants with normal hepatic function.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
08/07/2025
Locations: Research Site, San Antonio, Texas
Conditions: Hepatic Impairment
Register for Updates
A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
NCT06722157
Recruiting
This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine called BI 771716 with a medicine called pegcetacoplan. BI 771716 is being developed to treat people with geographic atrophy. Pegcetacoplan is a medicine already used to treat people with geographic atrophy. In this study, participants receive either BI 771716 or pegcetacoplan as injections in the eye. Participants are in the study for a little longe... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
08/07/2025
Locations: Retinal Consultants of San Antonio, San Antonio, Texas
Conditions: Macular Degeneration, Age-related, Geographic Atrophy
Register for Updates
An Efficacy and Safety Study of LTG-001 Following Abdominoplasty
NCT07102459
Recruiting
The goal of this clinical trial is to learn if LTG-001 works to treat post-operative / acute pain after an abdominoplasty procedure. It will also learn more information on the safety of LTG-001. The main questions it aims to answer are: Does drug LTG-001 treat the acute pain after surgical abdominoplasty over 48 hours? How tolerable is LTG-001 over 48 hours? What dose of LTG-001 is better for treating post-operative / acute pain? Participants will: Take LTG-001 bid after the surgical abdomin... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/07/2025
Locations: Endeavor Clinical Research, San Antonio, Texas
Conditions: Acute Pain, Postoperative Pain Control
Register for Updates
Evaluation of Non-Invasive Tests for Metabolic Liver Disease
NCT07122700
Recruiting
The Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) study is a comprehensive, multi-year collaborative effort to standardize, validate and advance the regulatory qualification of blood- and imaging-based biomarkers to diagnose and stage Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH). MASH is characterized by liver inflammation accompanied by simultaneous fat accumulation in the liver.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/07/2025
Locations: Endeavor Clinical Trials, San Antonio, Texas
Conditions: Metabolic Associated Fatty Liver Disease, Metabolic Associated Steatotic Liver Disease, Cirrhosis, Liver, NASH, Liver Fibrosis, Liver Fat, Liver Steatoses, Liver Inflammation
Register for Updates
Matrion Decellularized Placental Membrane Versus Conventional Wound Management in Subjects With Diabetic Foot Ulcers
NCT07116876
Recruiting
This study will evaluate Matrion™ (LifeNet Health, Inc., Virginia Beach, VA), a placental membrane product, as a treatment for diabetic foot ulcers compared to conventional wound care. Matrion is derived from donated human birth tissue and includes both the amniotic and chorionic layers, along with the trophoblast layer. It is minimally processed using a proprietary decellularization method and terminally sterilized to ensure the membrane is acellular and sterile, making it suitable for surgical... Read More
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
08/07/2025
Locations: Element Research Group, San Antonio, Texas
Conditions: Diabetic Foot Ulcer (DFU), Lower Extremity
Register for Updates
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
NCT07108166
Recruiting
The purpose of this randomized study is to demonstrate direct clinical benefit, i.e., observed benefits in how humans with COPD feel in terms of symptoms (e.g., cough frequency, shortness of breath, and other respiratory symptoms) and function (e.g., lung function, and six-minute walking test \[6MWT\]) after switching to THS compared to continuing to smoking cigarettes.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/07/2025
Locations: Element Research Group, San Antonio, Texas
Conditions: COPD, Smoking, Tobacco Use
Register for Updates
A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis
NCT06903065
Recruiting
The purpose of this study is to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and activity of RO7790121 in participants with advanced metabolic dysfunction-associated steatohepatitis (MASH) fibrosis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/07/2025
Locations: Pinnacle Clinical Research, PLLC, San Antonio, Texas
Conditions: MASH
Register for Updates
A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)
NCT06881251
Recruiting
The purpose of this study is to evaluate how well JNJ-95475939 works as compared to placebo in participants with moderate to severe atopic dermatitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Progressive Clinical Research, San Antonio, Texas
Conditions: Dermatitis, Atopic
Register for Updates
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491
Recruiting
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
Gender:
MALE
Ages:
Between 18 years and 130 years
Trial Updated:
08/06/2025
Locations: Research Site, San Antonio, Texas +1 locations
Conditions: Metastatic Castration-Sensitive Prostate Cancer
Register for Updates
A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke
NCT05953480
Recruiting
The purpose of this study is to evaluate the efficacy and safety of redasemtide in adult participants with acute ischemic stroke (AIS). This study consists of 2 cohorts, Cohort A and Cohort B. Cohort A (redasemtide or placebo) will enroll participants who are ineligible for systemic thrombolysis and/or mechanical recanalization therapy. Cohort B (redasemtide or placebo) will enroll participants who are eligible to receive or who have received systemic thrombolysis and/or mechanical recanalizatio... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: University Health-University Hospital, San Antonio, Texas
Conditions: Acute Ischemic Stroke
Register for Updates
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
NCT06638307
Recruiting
This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: South Texas Accelerated Research Therapeutics, San Antonio, Texas +1 locations
Conditions: Advanced Breast Cancer
Register for Updates